Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone
A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Compare the Safety and Efficacy of Nateglinide vs. Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Basal Insulin Glargine in Combination With Metformin and/or Thiazolidinedione (Pioglitazone or Rosiglitazone)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07974
- Novartis Pharmaceuticals
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male/female, age 18-78 inclusive
- Type 2 diabetes, taking glargine, metformin and/or thiazolidinedione for 3 months prior to screening, stable doses for 2 months prior to screening
- HbA1c 7.0-8.5% inclusive
- Fasting plasma glucose <240 mg/dL at screening
- Body Mass Index 22-41 kg/m2
Exclusion Criteria:
- Pregnant or nursing
- Other investigational drugs within 30 days of screening
- Treatment with other anti-diabetic medications other than metformin, glargine and/or thiazolidinedione
- History of type 1 diabetes
- Abnormal kidney function
- History of acute diabetic complications
- Congestive heart failure requiring treatment
- Myocardial infarction, coronary artery surgery, stroke within 6 months of screening
- Liver disease, liver enzymes more than 3 times upper limit of normal
- Fasting triglycerides >700 mg/dL within past 12 weeks
- Acute infections or other conditions that may affect blood sugar or may interfere with interpretation of study data
- Treatment with corticosteroids
- Blood donation within past 12 weeks
Other protocol-defined inclusion/exclusion criterial may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Change from baseline in hemoglobin (Hb)_A1c
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Change from baseline in 2-hour postprandial glucose during standardized meal test
|
|
Proportion of patients achieving American Diabetes Association ADA goal of HbA1c <7.0%
|
|
Proportion of patients achieving reduction in HbA1c of 0.5%
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CDJN608AUS13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.